Skip to main navigation

Skip to Content

Overview
Stock Information
SEC Filings
Corporate Governance
Company
Contact Us
ImmunityBio.com

Press Releases

Press Releases

Year

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Jan 14, 2026

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

Jan 14, 2026

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Jan 13, 2026

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

Jan 12, 2026

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 24 of 24

IR Tools

© 2026 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'ImmunityBio', 'ImmunityBio Care', 'Anktiva', 'ThAnktiva', 'haNK', 'taNK', 'ceNK', 'NK-92', 'Nant Cancer Vaccine', 'NANT 001', 'NANT XL', 'NANT 001 and Design', 'QUILT', 'Outsmart Your Disease', 'Smart Therapies for Difficult Diseases', 'Nantkwest', 'VivaBioCell', and 'Infacell' are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

NantKwest

Visit ImmunityBio.com

Social icons